# Histiocyte Society

Source: https://onco.cc/institutions/histiocyte-society/  
OnCo record `histiocyte-society` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The international society of doctors and scientists who study histiocytic disorders; its LCH trials, run since the 1990s, set the worldwide standard for treating Langerhans cell histiocytosis in children.

## Summary

Founded in 1985, the Histiocyte Society brings together clinicians and researchers working on Langerhans cell histiocytosis, haemophagocytic lymphohistiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease and juvenile xanthogranuloma. It has run the sequential international LCH-I (1991), LCH-II, LCH-III (2001-2008) and LCH-IV trials, which established vinblastine-prednisone as standard therapy and defined its duration, and the HLH-94 and HLH-2004 protocols. It publishes classification and consensus guidelines, holds an annual scientific meeting, and maintains registries that supported the recognition of histiocytoses as MAPK-driven clonal neoplasms.

## Fields

- Kind: Institution
- Last checked: 2026-09-10
- Tags: nci-coverage; paediatric
- City: Pitman, US
- Type: consortium
- Website: https://histiocytesociety.org

## Sources

- Histiocyte Society: https://histiocytesociety.org

## Connected records

- cancers: [Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms](https://onco.cc/cancers/histiocytoses/), [Langerhans cell histiocytosis (LCH)](https://onco.cc/cancers/langerhans-cell-histiocytosis/)
- drugs: [Vinblastine](https://onco.cc/drugs/vinblastine/)
- trials: [LCH-III](https://onco.cc/trials/lch-iii/)
- people: [Vasanta Nanduri](https://onco.cc/people/vasanta-nanduri/)
- bottlenecks: [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/)

---
JSON: https://onco.cc/api/v1/entities/histiocyte-society.json